|
||||||||||||||||||||||||||||
|
|
| Upcoming Programs | ||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Overview
More than 20 million people in the United States are affected by diabetes, with 1.5 million new cases appearing each year. Of this population, nearly 65% will die from heart disease or stroke, a rate that is 4-times higher than in the non-diabetic population. Individualized and early glycemic control is critical in the prevention and management of diabetes and in reducing cardiovascular risk. This activity will expose attendees to the relationship between insulin resistance, type 2 diabetes, and the resulting cardiovascular risk in an effort to uncover effective treatment strategies and patient-based therapeutic options.
Objectives
Utilize appropriate glucose-lowering agents to reduce A1C to * 7.0%
Minimize adverse events and cardiovascular risk associated with glycemic therapy by employing appropriate glucose, blood pressure, and serum cholesterol agents
Faculty
Stan Schwartz, MD, FACE, FACP
University of Pennsylvania Medical Group
Hospital of the University of Pennsylvania
Philadelphia, PA
Stephen Brunton, MD
Director
Faculty Development
Cabarrus/NorthEast Medical Center
Concord, NC
Overview
Irritable bowel syndrome (IBS) is a highly misunderstood functional bowel disorder that is underreported and underdiagnosed. Because IBS can be challenging to diagnose and manage, it is important that clinicians stay up-to-date on current developments of diagnostic and treatment options in IBS.
Objectives
Recognize the symptoms of IBS and employ ACG guidelines and Rome III criteria to make a symptom-based diagnosis of IBS
Implement a patient-centered and evidence-based approach to the treatment of IBS, taking patientsÕ treatment goals into consideration as well as the efficacy, safety, and mechanisms of action of available treatment options
Faculty
Suzanne Rose, MD, MSEd
Professor of Medical Education and Medicine, Division of Gastroenterology
Associate Dean for Academic and Student Affairs
Associate Dean for Continuing Medical Education
Mount Sinai School of Medicine
New York, NY
David A. Peura, MD
Professor of Medicine
University of Virginia Health Sciences Center
Charlottesville, VA
Overview
Bipolar disorder (BD) and major depressive disorder (MDD) are two of the most prevalent psychiatric disorders in adults. These conditions are associated with overlapping disorders of mood including anxiety and depression; differentiating the two disorders can be difficult and can lead to misdiagnosis and mismanagement. This activity will focus on practical approaches to the diagnosis and management of the Òdifficult-to-treatÓ patient presenting with depression associated with MDD and BD.
Objectives
Recognize overlapping symptomatology and comorbid psychiatric disorders that can complicate the differential diagnosis of depression
Design and implement practical strategies to diagnosis and manage the difficult-to-treat patient with depression associated with major depressive disorder and bipolar disorder
Faculty
Larry Culpepper, MD, MPH
Professor of Family Medicine
Department of Family Medicine Chair
Boston University School of Medicine
Chief of Family Practice
Boston Medical Center
Boston, MA
Joseph A. Lieberman III, MD, MPH
Professor of Family Medicine
Jefferson Medical College
Thomas Jefferson University
Associate Editor, Delaware Medical Journal
Philadelphia, PA
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
Richard E. Rupp, MD
Associate Director, Division of Adolescent and Behavioral Medicine
Associate Professor of Pediatrics
University of Texas Medical Branch at Galveston
Galveston, TX
Martin C. Mahoney, MD, PhD
Director, Cancer Prevention & Detection Center
Roswell Park Cancer Institute
Associate Professor of Family Medicine
State University of New York at Buffalo
Buffalo, NY
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the benefits and limitations of current treatment options for herpes zoster and postherpetic neuralgia (PHN)
Evaluate clinical trial results of the herpes zoster vaccine and discuss current recommendations of the Advisory Committee on Immunization Practices for the prevention of herpes zoster
Faculty
John W. Gnann, Jr., MD
Professor of Medicine, Pediatrics, and Microbiology
Department of Medicine, Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham VA Medical Center
Birmingham, AL
Wanda D. Filer, MD
Founder, Strategic Health Institute
York, PA
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Mark Lee Corbett, MD
University of Louisville
Louisville, KY
Dennis K. Ledford, MD
University of South Florida College of Medicine
Tampa, FL
Overview
This program will underscore the need for early, aggressive, combination BP treatment in order to reach JNC 7 goals, in light of the effect hypertension and diabetes has on the pathogenesis of hypertensive renal damage. It will explain the mechanisms of action of the various antihypertensive drug classes and how clinicians can use this understanding when selecting a drug regimen. Based on recent and ongoing trials, the safest and most efficacious drug combinations will be discussed.
Objectives
Develop appropriate combination therapy regimens individualized to each diabetic hypertensive patientÕs established risk and comorbid conditions
Demonstrate an understanding of the role of renin-aniotensin-aldosterone system blockers in the treatment of hypertension, the prevention of new onset diabetes, and the prevention of progression in diabetic nephropathy by selecting the most appropriate treatment regimen for diabetic hypertensive patients
Faculty
John R. Steinberg, MD
Volunteer Faculty
University of Maryland School of Medicine
Baltimore, MD
John R. Steinberg, MD
Volunteer Faculty
University of Maryland School of Medicine
Baltimore, MD
Overview
Atherothrombotic disease, including acute coronary syndrome, stroke/TIA and PAD (peripheral arterial disease), continues to be a world-wide challenge in terms of morbidity, premature death, and disability with tremendous costs to patients, health care systems and society. The diffuse nature of atherothrombosis (cardiovascular, cerebrovascular, or peripheral arterial) and the heightened risk of recurrence represent major challenges to the clinician. This lecture will overview current studies and treatment guidelines for PAD, ACS and Stroke and explore the role of primary care in long-term treatment of these patients.
Objectives
Identify the major risk factors for CAD (coronary artery disease), stroke, and PAD (peripheral arterial disease)
Describe 3 clinical conditions in which dual antiplatelet therapy is recommended
Faculty
Philip Altus, MD, MACP
Professor of Medicine Emeritus
University of South Florida
Tampa, FL
Randall M. Zusman, MD
Associate Professor of Medicine
Harvard Medical School
Director, Division of Hypertension and Vascular Medicine Massachusetts General Hospital
Boston, MA
Overview
Rheumatoid arthritis (RA) is a complex immunologic and chronic inflammatory disease that affects more than 2 million people in the United States. Characterized by inflammation of the joints, periarticular bone resorption and cartilage destruction, RA is also an inherently aggressive, systemic disease that leaves patients vulnerable to comorbidities such as cardiovascular disease, osteoporosis, lymphoma, infection, and stroke. While primary care clinicians may not directly treat the disease long term, they are the first to come in contact with potential RA patients. Therefore it is important for all clinicians to be aware of the necessary steps in RA diagnostic and treatment modalities.
Objectives
Identify 3 early warning signs of rheumatoid arthritis (RA)
Describe current and evolving treatment options for RA, and be alert to monitoring and side effects related to these therapies
Faculty
Arthur L. Weaver, MD, MS, FACP, MACR
Clinical Professor of Medicine
Rheumatology
University of Nebraska Medical Center
Omaha, NE
Joseph A. Markenson, MD
Overview
Nearly half the male patients over age 50 presenting to the primary care clinician have bothersome lower urinary tract symptoms (LUTS). Identifying and treating LUTS/ benign prostatic hyperplasia (BPH) can be both simple and practical for the PCP. This presentation outlines the first evidence-based algorithm for treating male LUTS created specifically for the needs of primary care clinicians.
Objectives
Identify appropriate treatment for LUTS/BPH based on a focused history and objective measures
Define a strategy to apply techniques and practices to effectively diagnose and initially assess patients with LUTS/benign prostatic hyperplasia (BPH)
Faculty
Scott MacDiarmid, MD
Director, Alliance Urology Specialists
Bladder Control & Pelvic Pain Center
Clinical Faculty, Depart of Urology
Wake Forest University
Greensboro, NC
David S. Goldstein, MD
Chesapeake Urology Associates, P.A.
Greater Baltimore Medical Center
Baltimore, MD